Macrogenics Inc. shares (NASDAQ:MGNX) climbed 16.7 percent to $21.06 on Wednesday as Janssen Biotech Inc. extended its collaboration with the company, agreeing to pay $75 million up front for a global license to MGD015, a preclinical bispecific antibody targeting CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors.